• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of pediatrics >Beneficial effects of creatine phosphate sodium for the treatment of Henoch-Schonlein purpura in patients with early renal damage detected using urinary kidney injury molecule-1 levels
【24h】

Beneficial effects of creatine phosphate sodium for the treatment of Henoch-Schonlein purpura in patients with early renal damage detected using urinary kidney injury molecule-1 levels

机译：尿酸磷酸钠对尿肾损伤分子-1水平检测出的早期肾损伤患者Henoch-Schonlein紫癜的治疗作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Henoch-Schonlein purpura (HSP) is a small-vessel disease in children that is often accompanied by kidney damage. Despite many efforts to improve the early assessment of renal injury in HSP patients, effective markers are still lacking. In recent years, the relationship between kidney injury molecule-1 (KIM-1) and tubulointerstitial injury has drawn much attention, especially regarding the diagnostic potential of serum and urinary KIM-1 levels. However, the diagnostic value of KIM-1 for detecting urinary kidney injury in HSP patients is still elusive. Furthermore, the treatment of Henoch-Schonlein purpura nephritis (HSPN) relies on the clinician's experience without performing renal biopsy, so it is important to find an effective biomarker and therapy. In the present study, we investigated the diagnostic value of urinary KIM-1 for early renal injury in HSP patients enrolled in a prospective, single-center study. Urinary KIM-1 levels were measured in 27 patients with HSP, 32 patients with HSPN (21 HSPN patients had undergone renal biopsy), and 16 healthy donors, as normal controls. The HSPN patients were randomly divided to receive either routine therapy (n = 13) or routine treatment combined with creatine phosphate sodium (CP) (n = 19). Urinary KIM-1 levels were significantly greater in the HSP and HSPN groups than those in the healthy control group (P < 0.01), and were significantly greater in the HSPN group than in the HSP group (P < 0.01). The urinary KIM-1 levels decreased significantly after 10-14 days of treatment with CP compared with conventional therapy (P < 0.05).
机译：过敏性紫癜（HSP）是儿童的小血管疾病，通常伴有肾脏损害。尽管为改善HSP患者的肾损伤的早期评估做出了许多努力，但仍然缺乏有效的标记物。近年来，肾损伤分子1（KIM-1）与肾小管间质损伤之间的关系引起了人们的广泛关注，特别是在血清和尿KIM-1水平的诊断潜力方面。然而，KIM-1在检测HSP患者尿肾损伤中的诊断价值仍然难以捉摸。此外，Henoch-Schonlein紫癜性肾炎（HSPN）的治疗依赖于临床医生的经验而无需进行肾活检，因此寻找有效的生物标志物和治疗方法很重要。在本研究中，我们调查了一项前瞻性，单中心研究中尿KIM-1对HSP患者早期肾损伤的诊断价值。作为正常对照，测量了27例HSP患者，32例HSPN患者（21例接受肾活检的HSPN患者）和16例健康供体的尿KIM-1水平。 HSPN患者随机分为常规治疗（n = 13）或常规治疗与肌酸磷酸钠（CP）联合治疗（n = 19）。 HSP和HSPN组的尿KIM-1水平显着高于健康对照组（P <0.01），HSPN组的尿KIM-1水平显着高于HSP组（P <0.01）。与常规治疗相比，CP治疗10-14天后尿KIM-1水平显着降低（P <0.05）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号